Intensity Therapeutics, Inc. (INTS)
| Market Cap | 9.53M -72.1% |
| Revenue (ttm) | n/a |
| Net Income | -12.04M |
| EPS | -4.44 |
| Shares Out | 3.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,097 |
| Open | 2.940 |
| Previous Close | 3.000 |
| Day's Range | 2.800 - 2.940 |
| 52-Week Range | 2.800 - 15.000 |
| Beta | 3.04 |
| Analysts | Strong Buy |
| Price Target | 18.67 (+539.38%) |
| Earnings Date | Nov 5, 2026 |
About INTS
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for INTS stock is "Strong Buy." The 12-month stock price target is $18.67, which is an increase of 539.38% from the latest price.
News
Intensity Therapeutics price target lowered to $8 from $12 at StoneX
StoneX lowered the firm’s price target on Intensity Therapeutics (INTS) to $8 from $12 and keeps a Speculative Buy rating on the shares.
Intensity Therapeutics reports Q3 EPS ($1.09), consensus (99c)
“We are excited that recruitment of patients has been reinitiated in both of our trials,” stated Lewis H. Bender, President and CEO of Intensity Therapeutics (INTS), Inc. “In the Phase…
Intensity Therapeutics Earnings Call Transcript: Q3 2026
Enrollment resumed in both clinical studies, while capital remains the key constraint on expansion. Early INVINCIBLE-4 data showed 71% pCR with INT230-6 vs. 42% with standard care, based on small patient numbers.
Intensity Therapeutics Quarterly report: Q3 2026
Intensity Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Intensity Therapeutics Earnings release: Q3 2026
Intensity Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
New patient enrollment activities resumed in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study in the third quarter of 2026 New patient enrollment and treatment resu...
Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026
Company to hold a conference call at 8AM ET on November 5, 2026 to review results and provide a corporate update SHELTON, Conn., Oct. 30, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"...
Intensity reports data from Cohort A in the INVINCIBLE-4 Study
Intensity Therapeutics (INTS) announced data for the first seven patients in Cohort A in the INVINCIBLE-4 Study will be presented in an ePoster by The Swiss Cancer Institute, the Company’s…
Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting
Pathological complete response (pCR) achieved in the breast (ypT0/Tis) and affected lymph nodes (ypN0) in 5 out of 7 patients (71%; 95% CI 29-96%) in the INT230-6 plus standard-of-care cohort No invas...
Intensity Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A novel cancer therapy using a supramolecular complex is showing promising results in phase II and III trials, with improved survival and safety outcomes. The company has secured key regulatory designations, maintains strong financial health, and is actively pursuing partnerships.
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SHELTON, Conn., Sept. 8, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and devel...
Intensity Therapeutics price target raised to $7 from $5 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Intensity Therapeutics (INTS) to $7 from $5 and keeps a Buy rating on the shares post the Q2 report. The Phase 3…
Intensity Therapeutics price target lowered to $15 from $30 at Alliance Global
Alliance Global analyst James Molloy lowered the firm’s price target on Intensity Therapeutics (INTS) to $15 from $30 and keeps a Buy rating on the shares, citing delays in re-starting…
Intensity Therapeutics Earnings Call Transcript: Q2 2026
R&D and G&A expenses rose in Q2 2026, driving a 19% increase in net loss. Clinical trial enrollment resumed for both INVINCIBLE-3 and INVINCIBLE-4, with promising early efficacy data in TNBC. Additional capital is needed to fully activate sites and accelerate trial progress.
Intensity Therapeutics Quarterly report: Q2 2026
Intensity Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Intensity Therapeutics Earnings release: Q2 2026
Intensity Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Intensity Therapeutics reports Q2 EPS ($1.11), consensus (77c)
As of June 30, cash and cash equivalents totaled $9.5M. During Q2, the company raised $1.7M under the ATM, for net proceeds of $1.6M. “We are pleased that the capital…
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026 Patient treatment restarted in the presur...
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
Company to hold a conference call at 8AM ET on August 11, 2026 to review results and provide a corporate update SHELTON, Conn., Aug. 4, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" o...
Intensity Therapeutics provides update in Invincicle-4 study
Intensity Therapeutics (INTS) announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in Switzerland. The trial analyzes INT230-6 given before administration of the stand...
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
First patients dosed in Switzerland SHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology compan...
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer Over 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper published...
Intensity Therapeutics Transcript: AGM 2026
The meeting saw the re-election of two directors, approval of auditor ratification, and amendments to stock plans. All proposals passed by majority vote, and no questions were raised during the Q&A session.
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Company receives the Cancer Treatment Technology Innovator of the Year award SHELTON, Conn., May 14, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a...
Intensity Therapeutics reports Q1 EPS (96c), consensus ($1.09)
Cash and cash equivalents of $10.2M as of March 31. Lewis Bender, Founder, President, and CEO, stated, “The Company made excellent progress in the first quarter. We announced early data…